Research In Biomedical Sciences Research Articles

Public financing of health research in Chile

In Chile, researchers can apply to public research funds through specific research projects and must compete with other professionals of other disciplines. To perform a critical assessment of the allocation of public funds for health research in Chile by a public institution called CONICYT. A database was constructed with health projects financed by CONICYT, between 2002 and 2006. Projects were classified (according to their titles) in three methodological categories and nine topics. Age, gender and region where the main researcher is based, were also recorded. 768 research projects were analyzed. Biomedical, clinical and public health research projects accounted for 66, 24 and 10% of allocated funds, respectively. Main researchers were female in 31 % of projects, their mean age was 52 years and 76% worked in the Metropolitan region. These results show that some objectives of the National Research System lead by CONICYT, such as using research as a tool for regional development and allocating funds for conditions with a large burden, are not been met.

Clinical Cancer Advances 2009: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology

A MESSAGE FROM ASCO'S PRESIDENT As this report demonstrates—and as history shows—investment in clinical cancer research pays off. Since 1990, cancer mortality rates have declined by 15%. Today, two thirds of patients survive at least 5 years after diagnosis, compared with just half of patients 40 years ago. Patient quality of life has improved dramatically. In addition, thanks to basic research advances, we are entering an era of personalized cancer medicine, in which treatment is tailored to the unique genetics of the individual. Clinical cancer research is finally receiving an urgently needed boost in investment. For the first time in 5 years, federal funding for research has increased. The economic stimulus package infused billions into short-term biomedical research projects, and President Obama has pledged to invest in “a cure for cancer in our time.” However, despite this progress, cancer remains the number-two killer of Americans. Incidence is projected to nearly double by 2020 as the population grows and ages. Scientifically, cancer is highly complex; it is not one disease, but many, and is increasingly defined by thousands of genetic variations, epigenetic changes, post-transcriptional modifications, and combinations of these mechanisms, rather than by site of origin. Unraveling these complexities begins to explain why some cancers are especially resistant to treatment, a fact we have known for some time. Other cancers are fatal because they are typically diagnosed late in the course of disease, when treatment is less effective. To achieve new breakthroughs, the scale of the national response must match the scale of the problem. Years of flat federal research funding have resulted in abandoned or stalled clinical research projects, a deteriorating research infrastructure, and the loss of talented physicians to other fields. In this report, the American Society of Clinical Oncology (ASCO) commends the recent increases in funding and calls on Congress to make a multiyear commitment to sustained increases in clinical cancer research at the National Institutes of Health and National Cancer Institute. Major advances in cancer treatment cannot be expected to emerge without consistent and predictable investment at the federal level. Although a robust clinical research enterprise is essential to improving patient care, advances mean little if they do not reach people in need. For people with cancer, lack of health insurance can be the difference between life and death. It is estimated that 32% of patients with cancer in the United States are uninsured at some point during their treatment, and more than a quarter opt not to seek treatment as a result. We must end the inequality in health care access. ASCO believes that health care reform must ensure that everyone diagnosed with cancer has the coverage necessary to receive high-quality treatment. To that end, we have made access to cancer care a top priority in our advocacy agenda. I believe the advances described in this report should give all of us cause for hope. Although there is a long road ahead, by investing in a robust national clinical research program and by improving access to high-quality care, we can give every patient the best chance of survival. Douglas Blayney, MD President American Society of Clinical Oncology

Translating molecular medicine into clinical tools: doomed to fail by neglecting basic preanalytical principles

This commentary discusses a study on measurements of matrix metalloproteinase 9 (MMP-9) in serum of pseudoxanthoma elasticum patients recently published in Journal of Molecular Medicine. This study can be considered the typical "obstacle" to effective translational medicine as previously documented in JTM journal. Although serum has been frequently proven as inappropriate sample for determining numerous circulating MMPs, among them MMP-9, there are over and over again studies, as in this case, that measure MMP-9 in serum. Comparative measurements in serum and plasma samples demonstrated higher concentrations for MMP-9 in serum due to the additional release from leukocytes and platelets following the coagulation/fibrinolysis process. From this example it can be concluded that translating basic research discoveries into clinical tools needs a more intensive exchange between basic biomedical research and clinical scientists already in an early stage. Otherwise a lost of translation, as discussed in JTM journal, seems to be inevitable.

25 years of HBSC: challenges and successes

David McQueen is a Senior Biomedical Research Scientist at the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia, USA. Since 1998 he has been the Associate Director for Global Health Promotion in the Office of the Director at the National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP). Prior to that he was Director of the Division of Adult and Community Health at NCCDPHP and Acting Director of the Office of Surveillance and Analysis at (NCCDPHP), as well as Chief of the nationwide Behavioral Risk Factor Surveillance System. Prior to joining CDC he was the founding Director of the Research Unit in Health and Behavioural Change at the University of Edinburgh, Scotland (1983-1992), and prior to that Associate Professor of Behavioral Sciences at the Johns Hopkins University School of Hygiene and Public Health in Baltimore. His Doctoral training was in behavioral sciences at the Johns Hopkins University.

HPC and Grid Computing for Integrative Biomedical Research

Integrative biomedical research projects query, analyze, and integrate many different data types and make use of datasets obtained from measurements or simulations of structure and function at multiple biological scales. With the increasing availability of high-throughput and high-resolution instruments, the integrative biomedical research imposes many challenging requirements on software middleware systems. In this paper, we look at some of these requirements using example research pattern templates. We then discuss how middleware systems, which incorporate Grid and high-performance computing, could be employed to address the requirements.

How to Efficiently Obtain Human Tissues to Support Specific Biomedical Research Projects

The purpose of this article is to facilitate access of biomedical researchers to human tissues by describing the types of tissue resources available to researchers, common problems with tissue requests that may limit tissue availability to specific investigators, and steps that can be taken to simplify requests to avoid these problems and enhance access to tissue. Types of human tissue resources available to investigators are described and reviewed, and the experience of the University of Alabama Tissue Collection and Banking Facility (TCBF) is described. Our experience indicates that typical problems with requests for tissue fall into the following categories: (1) size and number of specimens, (2) type (rarity and availability), (3) time constraints, (4) demand versus supply, (5) limitations and goals of the resource, and (6) time and resources that can be devoted to a specific request. Investigators should review their requests for human tissues to support their research if they are not receiving adequate quantities of tissue. This review is best accomplished by discussing their requests with the tissue resource and correcting specific limitations that block access to the tissues they need.

Biomedical Scientists' Perceptions of Ethical and Social Implications: Is There a Role for Research Ethics Consultation?

BackgroundResearch ethics consultation programs are being established with a goal of addressing the ethical, societal, and policy considerations associated with biomedical research. A number of these programs are modelled after clinical ethics consultation services that began to be institutionalized in the 1980s. Our objective was to determine biomedical science researchers' perceived need for and utility of research ethics consultation, through examination of their perceptions of whether they and their institutions faced ethical, social or policy issues (outside those mandated by regulation) and examination of willingness to seek advice in addressing these issues. We conducted telephone interviews and focus groups in 2006 with researchers from Stanford University and a mailed survey in December 2006 to 7 research universities in the U.S.FindingsA total of 16 researchers were interviewed (75% response rate), 29 participated in focus groups, and 856 responded to the survey (50% response rate). Approximately half of researchers surveyed (51%) reported that they would find a research ethics consultation service at their institution moderately, very or extremely useful, while over a third (36%) reported that such a service would be useful to them personally. Respondents conducting human subjects research were more likely to find such a service very to extremely useful to them personally than respondents not conducting human subjects research (20% vs 10%; chi2 p<0.001).ConclusionOur findings indicate that biomedical researchers do encounter and anticipate encountering ethical and societal questions and concerns and a substantial proportion, especially clinical researchers, would likely use a consultation service if they were aware of it. These findings provide data to inform the development of such consultation programs in general.

Musings on genome medicine: the slow but inexorable process of medical care reform in the United States

The current healthcare system in the United States is unsustainable, but any attempts at improvement must be carefully managed to avoid weakening the country's contribution to biomedical science research and the future of genome medicine.

More Than Skin Deep

BIOMEDICAL RESEARCHScientists still don't know what causes scleroderma, a complex disease often marked by toughening skin and widespread internal fibrosis, but they're developing potential treatments nonetheless.

The baffling multitude of disease models for the study of human disease – how can the scientist navigate the huge amount of data and receive guidance?

Funding from external sources is the lifeline for most biomedical research scientists. In the USA, the National Institutes of Health (NIH), composed of 27 institutes and centers, is the primary federal agency for conducting and supporting medical research. One of these centers, the National Center for Research Resources (NCRR) provides financial support and resources to clinical or translational scientists working to understand human disease. Through the Division of Comparative Medicine, the NCRR funds projects focused on the development and use of model organisms to understand, diagnose, prevent and treat disease. Here, officials within the NCRR's Division of Comparative Medicine discuss some of the funding opportunities and resources available to researchers who use model organisms, and their perspectives on the future of model organism research.

A Cryptographic Approach to Securely Share and Query Genomic Sequences

To support large-scale biomedical research projects, organizations need to share person-specific genomic sequences without violating the privacy of their data subjects. In the past, organizations protected subjects' identities by removing identifiers, such as name and social security number; however, recent investigations illustrate that deidentified genomic data can be "reidentified" to named individuals using simple automated methods. In this paper, we present a novel cryptographic framework that enables organizations to support genomic data mining without disclosing the raw genomic sequences. Organizations contribute encrypted genomic sequence records into a centralized repository, where the administrator can perform queries, such as frequency counts, without decrypting the data. We evaluate the efficiency of our framework with existing databases of single nucleotide polymorphism (SNP) sequences and demonstrate that the time needed to complete count queries is feasible for real world applications. For example, our experiments indicate that a count query over 40 SNPs in a database of 5000 records can be completed in approximately 30 min with off-the-shelf technology. We further show that approximation strategies can be applied to significantly speed up query execution times with minimal loss in accuracy. The framework can be implemented on top of existing information and network technologies in biomedical environments.

A nonparametric smoothing method for assessing GEE models with longitudinal binary data

Studies involving longitudinal binary responses are widely applied in the health and biomedical sciences research and frequently analyzed by generalized estimating equations (GEE) method. This article proposes an alternative goodness-of-fit test based on the nonparametric smoothing approach for assessing the adequacy of GEE fitted models, which can be regarded as an extension of the goodness-of-fit test of le Cessie and van Houwelingen (Biometrics 1991; 47:1267-1282). The expectation and approximate variance of the proposed test statistic are derived. The asymptotic distribution of the proposed test statistic in terms of a scaled chi-squared distribution and the power performance of the proposed test are discussed by simulation studies. The testing procedure is demonstrated by two real data.

Facebook for Scientists: Requirements and Services for Optimizing How Scientific Collaborations Are Established

Background As biomedical research projects become increasingly interdisciplinary and complex, collaboration with appropriate individuals, teams, and institutions becomes ever more crucial to project success. While social networks are extremely important in determining how scientific collaborations are formed, social networking technologies have not yet been studied as a tool to help form scientific collaborations. Many currently emerging expertise locating systems include social networking technologies, but it is unclear whether they make the process of finding collaborators more efficient and effective.Objective This study was conducted to answer the following questions: (1) Which requirements should systems for finding collaborators in biomedical science fulfill? and (2) Which information technology services can address these requirements?Methods The background research phase encompassed a thorough review of the literature, affinity diagramming, contextual inquiry, and semistructured interviews. This phase yielded five themes suggestive of requirements for systems to support the formation of collaborations. In the next phase, the generative phase, we brainstormed and selected design ideas for formal concept validation with end users. Then, three related, well-validated ideas were selected for implementation and evaluation in a prototype.Results Five main themes of systems requirements emerged: (1) beyond expertise, successful collaborations require compatibility with respect to personality, work style, productivity, and many other factors (compatibility); (2) finding appropriate collaborators requires the ability to effectively search in domains other than your own using information that is comprehensive and descriptive (communication); (3) social networks are important for finding potential collaborators, assessing their suitability and compatibility, and establishing contact with them (intermediation); (4) information profiles must be complete, correct, up-to-date, and comprehensive and allow fine-grained control over access to information by different audiences (information quality and access); (5) keeping online profiles up-to-date should require little or no effort and be integrated into the scientist’s existing workflow (motivation). Based on the requirements, 16 design ideas underwent formal validation with end users. Of those, three were chosen to be implemented and evaluated in a system prototype, “Digital|Vita”: maintaining, formatting, and semi-automated updating of biographical information; searching for experts; and building and maintaining the social network and managing document flow.Conclusions In addition to quantitative and factual information about potential collaborators, social connectedness, personal and professional compatibility, and power differentials also influence whether collaborations are formed. Current systems only partially model these requirements. Services in Digital|Vita combine an existing workflow, maintaining and formatting biographical information, with collaboration-searching functions in a novel way. Several barriers to the adoption of systems such as Digital|Vita exist, such as potential adoption asymmetries between junior and senior researchers and the tension between public and private information. Developers and researchers may consider one or more of the services described in this paper for implementation in their own expertise locating systems.

Paradigm errors in the old biomedical science

The aim of this article was to review the basic drawbacks of the deterministic and reductionistic thinking in biomedical science and to provide ways for dealing with them. The present paradigm of research in biomedical science has not got rid of the errors of the old science yet, i.e. the errors of absolute determinism and reductionism. These errors restrict the view and thinking of scholars engaged in the studies of complex and dynamic phenomena and mechanisms. Recently, discussions on science paradigm aimed at spreading the new science paradigm that of complex dynamic systems as well as chaos theory are in progress all over the world. It is for the nearest future to show which of the two, the old or the new science, will be the winner. We have come to the main conclusion that deterministic and reductionistic thinking applied in improper way can cause substantial damage rather than prove benefits for biomedicine science.

Obstacles to European research projects with data and tissue: Solutions and further challenges

Most European biomedical research projects are about data. Research with tissue is about data as well; data will accompany the tissue, and data will be derived from analysing the tissue. Data can be merged with data from various sources, copied and re-analysed in the context of European projects. Privacy enhancing technologies (PET) should be used for transferring data from participating centres to the level where data are being merged. PET provide coding techniques which allow donors to be anonymised and still uniquely discernable. It is defended that under certain conditions two-way coded data can be considered as anonymous data in the sense of the European Data Protection Directive. Divergent interpretations of this Directive and most of all about the concept of coded-anonymised data is one of the main obstacles to observational research in Europe. The Data Protection Authorities will have to relax the extremely high threshold before data cannot be considered personal data anymore. Arguments are given for such relaxation. Besides the logic and logistics of data transfer in European projects, it is also about trust and a realistic risk assessment. In spite of the massive dataflow in European research projects no breach of confidentiality has ever been reported. The ethical rationale of such projects can be based on the principles of citizenship and solidarity provided that certain safeguards are met by which that research will remain observational. However, if the project does not preclude individual feed-back on the outcomes of research, as in theory would be possible with two-way coded tissue, that tissue cannot be considered anonymous. It is argued that in most tissuebanking projects individual feed-back should be excluded. Tissuebanking for research should not turn into medical screening without applying the established criteria for screening to it. If individual feed-back is not foreseen, two-way tissue should be considered anonymous, under the same conditions as two-way coded data. Good research governance is proposed as the way forward in the longer run. Good research governance is about a fair balance between the interests of all stakeholders. It should make the basic principles transparent on which observational research projects are based in line with European solidarity-based healthcare systems. It should encompass principles on how the general results of research will be disseminated, ‘conflict of interests’ policies, how the issues of intellectual property rights are dealt with, how the confidentiality of personal data of donors is maintained, etc. This should not become an extra bureaucratic layer. A good research governance framework should not establish rules but principles which provide enough flexibility for the specifics of a project, according to the ‘comply or explain’ principle. Such research governance should be developed bottom-up, by researchers together with the most interested stakeholders, patient organisations. Patients as ‘biosocial citizens’ are the natural allies of researchers against the ‘paternalistic attitudes’ of some ethicists and regulators.

Limits of bibliometrics indicators in biomedical scientific research evaluation.

The use of bibliometrics indicators to study research activity is based on which the scientific publications are essential product of this activity, and provide information about the research process, its volume, evolution, visibility and structure. So, they allow to value the scientific activity, and influences (or impact) of the work and the sources. The bibliometrics studies, altogether with other indicators, allows an objective quantification of the knowledge, and are harnessed by the present explosion of the knowledge and its compilation in bibliographical data bases.

The NIH Roadmap: Are Psychologists In or Out?

Psychologists often express concerns about the inclusion of psychology in the National Institutes of Health (NIH) Roadmap initiative. Most Roadmap themes focus on biomedical research, forming the basis for psychologists' concerns. Although most Roadmap funding goes toward biomedical research, social and behavioral scientists do win support. It is reasonable to ask, however, why the Roadmap is focused so exclusively on medical research. One explanation is that medical interventions are seen as the natural translation of basic biomedical research, whereas psychological interventions are not perceived as following from basic behavioral research. Psychologists working in academic health centers represent the best opportunity for creating such linkages, and therefore the best potential bridge for psychology connecting to the NIH Roadmap.

Exploring the Relationship Between Scientist Human Capital and Firm Performance: The Case of Biomedical Academic Entrepreneurs in the SBIR Program

Do academic scientists bring valuable human capital to the companies they found or join? If so, what are the particular skills that compose their human capital and how are these skills related to firm performance? This paper examines these questions using a particular group of academic entrepreneurs - biomedical research scientists who choose to commercialize their knowledge through the U.S. Small Business Innovation Research Program. Our conceptual framework assumes the nature of an academic entrepreneurs' prior research reflects the development of their human capital. We highlight differences in firm performance that correlate with differences in the scientists' research orientations developed during their academic careers. We find that biomedical academic entrepreneurs with human capital oriented toward exploring scientific opportunities significantly improve their firms' performance of research tasks such as proof of concept studies. Biomedical academic entrepreneurs with human capital oriented toward exploring commercial opportunities significantly improve their firms' performance of invention oriented tasks such as patenting. Consistent with prior evidence, there also appears to be a form of diminishing returns to scientifically oriented human capital in a commercialization environment. Holding the commercial orientation of the scientists' human capital constant, we find that increasing their human capital for identifying and exploring scientific opportunities significantly detracts from their firms' patenting performance.

The reincarnation of a biomedical researcher: from bench science to medical education

After 33 years as a biomedical research scientist, I embarked on a new career in medical education. The transformation was awkward, difficult and exciting. Although I had assumed that previous experience in research and scholarship would stand me in good stead, such was hardly the case. I had to learn to navigate a strange new literature, replete with terms that I did not understand, and to deal with concepts that challenged my physico-chemical mindset. As I learned, I found myself discovering a field rich in essential questions, controversial hypotheses, and important potential applications. With my newly acquired knowledge and skills, I began to reflect on my own educational endeavors. I identified a number of outstanding issues and I designed studies to address them. What made these investigations particularly significant for me was their applicability. Although medical education is an exciting and meaningful career path, because of its low profile in most medical schools, few faculty are aware of the academic opportunities that it affords.

High-tech biomedical research: lessons from Iran's experience

Iran has recently made a significant progress in the field of biomedical science and launched an appreciable number of new high-tech biomedical research projects. Review of Iran's experience in advancing its biomedical research and the pitfalls the country encountered during the years of its progress could be of interest to other countries with similar technological conditions. As needs assessment and human resources have pivotal roles in any research infrastructure, here, we have delineated these factors and explored ways by which optimum advantage could be gained from them.